| 7504 | Humans |
| 5276 | Male |
| 4890 | Female |
| 3899 | Middle Aged |
| 3700 | Nervous system diseases |
| 3338 | Aged |
| 2695 | Adult |
| 2676 | Parkinson disease |
| 2362 | Human |
| 1951 | Parkinson's disease |
| 960 | Severity of Illness Index |
| 944 | Aged, 80 and over |
| 939 | Parkinson Disease (drug therapy) |
| 933 | Treatment |
| 845 | Case study |
| 839 | Dystonia |
| 835 | Parkinson Disease (physiopathology) |
| 795 | Parkinson Disease (complications) |
| 736 | Magnetic Resonance Imaging |
| 643 | Parkinson Disease (diagnosis) |
| 592 | Antiparkinson Agents (therapeutic use) |
| 572 | Treatment Outcome |
| 572 | Adolescent |
| 547 | Exploration |
| 542 | Animals |
| 540 | Neurologic Examination |
| 529 | Levodopa (therapeutic use) |
| 518 | Tremor |
| 515 | Chemotherapy |
| 485 | Electromyography |
| 475 | Brain (pathology) |
| 467 | Parkinsonism |
| 467 | Follow-Up Studies |
| 455 | Diagnosis, Differential |
| 445 | Neuropsychological Tests |
| 411 | Parkinson Disease (pathology) |
| 408 | Parkinson Disease (genetics) |
| 405 | Levodopa |
| 401 | Child |
| 384 | Parkinson Disease (epidemiology) |
| 379 | Case-Control Studies |
| 373 | Antiparkinson Agents (adverse effects) |
| 367 | Parkinson Disease (therapy) |
| 365 | Levodopa (adverse effects) |
| 341 | Parkinson Disease (psychology) |
| 339 | Disease Progression |
| 331 | Dose-Response Relationship, Drug |
| 328 | Retrospective Studies |
| 327 | Time Factors |
| 321 | Questionnaires |
| 299 | Complication |
| 297 | Dyskinesia |
| 294 | Young Adult |
| 289 | Analysis of Variance |
| 285 | Diagnosis |
| 282 | Myoclonus |
| 280 | Disability Evaluation |
| 276 | Mutation |
| 274 | Nuclear magnetic resonance imaging |
| 260 | Double-Blind Method |
| 254 | dystonia |
| 254 | Antiparkinson agent |
| 253 | Risk Factors |
| 251 | Age of Onset |
| 249 | Deep Brain Stimulation (methods) |
| 243 | Phenotype |
| 236 | Genotype |
| 235 | Neurologic Examination (drug effects) |
| 225 | Drug Therapy, Combination |
| 224 | Prevalence |
| 223 | Mutation (genetics) |
| 221 | Toxicity |
| 221 | Multiple system atrophy |
| 216 | Reproducibility of Results |
| 213 | Deep brain stimulation |
| 210 | Brain Mapping |
| 205 | Magnetic Resonance Imaging (methods) |
| 205 | Comparative study |
| 202 | Dystonia (physiopathology) |
| 202 | Dystonia (diagnosis) |
| 200 | Huntington disease |
| 196 | Pedigree |
| 196 | Cognition Disorders (etiology) |
| 194 | deep brain stimulation |
| 194 | Symptomatology |
| 192 | Electroencephalography |
| 189 | Basal ganglion |
| 188 | Pathophysiology |
| 184 | Videotape Recording |
| 181 | Prospective Studies |
| 181 | Levodopa (administration & dosage) |
| 181 | DNA Mutational Analysis |
| 180 | Tremor (physiopathology) |
| 177 | Dominance, Cerebral (physiology) |
| 176 | Subthalamic nucleus |
| 175 | Tremor (diagnosis) |
| 174 | Antiparkinson Agents (administration & dosage) |
| 169 | Involuntary movement |
| 168 | Age Factors |
| 167 | Longitudinal Studies |
| 167 | Dopamine |
| 166 | Epidemiology |
| 165 | Risk factor |
| 164 | Tomography, Emission-Computed, Single-Photon |
| 164 | Parkinson Disease (metabolism) |
| 164 | Cohort Studies |
| 161 | Quality of Life |
| 161 | Prognosis |
| 161 | Cognition Disorders (diagnosis) |
| 159 | Statistics, Nonparametric |
| 157 | Chorea |
| 157 | Child, Preschool |
| 156 | Animal |
| 155 | Cross-Sectional Studies |
| 152 | Drug Administration Schedule |
| 151 | Reference Values |
| 149 | Movement Disorders (etiology) |
| 148 | Movement Disorders (diagnosis) |
| 148 | Dopamine (metabolism) |
| 147 | Dyskinesia, Drug-Induced (etiology) |
| 146 | Tremor (etiology) |
| 146 | Dementia |
| 144 | Movement Disorders (physiopathology) |
| 143 | Dopamine Agonists (therapeutic use) |
| 142 | Depression |
| 141 | Restless legs syndrome |
| 141 | Functional Laterality (physiology) |
| 139 | Disease Models, Animal |
| 139 | Brain (physiopathology) |
| 136 | Psychiatric Status Rating Scales |
| 136 | Parkinson Disease (etiology) |
| 135 | Family Health |
| 134 | parkinsonism |
| 134 | essential tremor |
| 134 | Tomography, X-Ray Computed |
| 134 | Substantia Nigra (pathology) |
| 134 | Huntington's disease |
| 134 | Differential diagnostic |
| 133 | Muscle, Skeletal (physiopathology) |
| 132 | Reaction Time (physiology) |
| 132 | Parkinson Disease (radionuclide imaging) |
| 131 | Emission tomography |
| 130 | Evolution |
| 130 | Brain (metabolism) |
| 129 | Psychomotor Performance (physiology) |
| 129 | Functional Laterality |
| 129 | Dystonia (genetics) |
| 128 | levodopa |
| 128 | Posture |
| 128 | Elderly |
| 127 | Parkinson Disease (surgery) |
| 124 | multiple system atrophy |
| 124 | Pathogenesis |
| 124 | Parkinsonian Disorders (genetics) |
| 124 | Dystonia (drug therapy) |
| 123 | Dopamine agonist |
| 122 | Psychometrics |
| 121 | Quality of life |
| 121 | Genetic Predisposition to Disease |
| 120 | Positron emission tomography |
| 120 | Dystonia (etiology) |
| 118 | Parkinsonian Disorders (diagnosis) |
| 114 | Electrodes, Implanted |
| 113 | Video recording |
| 113 | Subthalamic Nucleus (physiology) |
| 113 | Motor Cortex (physiopathology) |
| 113 | Idiopathic |
| 112 | Myoclonus (physiopathology) |
| 112 | Cerebral Cortex (physiopathology) |
| 112 | Atrophy |
| 111 | Motor Activity (physiology) |
| 110 | Sensitivity and Specificity |
| 110 | Electromyography (methods) |
| 109 | Huntington Disease (genetics) |
| 109 | Bontoxilysin |
| 107 | Cognitive disorder |
| 106 | Degeneration |
| 105 | Basal Ganglia (pathology) |
| 104 | Polysomnography |
| 104 | Botulinum Toxins, Type A (therapeutic use) |
| 102 | Mental Status Schedule |
| 102 | Gilles de la Tourette syndrome |
| 102 | Brain (vertebrata) |
| 101 | Protein-Serine-Threonine Kinases (genetics) |
| 101 | Movement (physiology) |
| 100 | Nerve Tissue Proteins (genetics) |
| 100 | Injections, Intramuscular |
| 100 | History, 20th Century |
| 99 | Point Mutation (genetics) |
| 99 | Parkinsonian Disorders (drug therapy) |
| 99 | Corpus Striatum (pathology) |
| 98 | Statistics as Topic |
| 98 | Parkinson Disease, Secondary (chemically induced) |
| 98 | Image Processing, Computer-Assisted |
| 98 | Cerebral Cortex (pathology) |
| 98 | Ataxia |
| 97 | Syndrome |
| 97 | Encephalon |
| 97 | Cognition |
| 97 | Agonist |
| 96 | Sleep |
| 96 | Pilot Projects |
| 95 | tremor |
| 95 | Predictive Value of Tests |
| 95 | Electrodiagnosis |
| 95 | Dystonic Disorders (physiopathology) |
| 95 | Blepharospasm |
| 94 | Photon |
| 94 | Parkinsonian Disorders (pathology) |
| 94 | Long term |
| 94 | Dystonic Disorders (diagnosis) |
| 93 | Etiology |
| 93 | Activities of Daily Living |
| 92 | restless legs syndrome |
| 92 | Dystonic Disorders (genetics) |
| 92 | Degenerative disease |
| 92 | Cerebellum |
| 91 | Supranuclear ophthalmoplegia |
| 91 | Multiple System Atrophy (diagnosis) |
| 91 | Clinical trial |
| 91 | Cerebellum (pathology) |
| 90 | Gait Disorders, Neurologic (etiology) |
| 90 | Family study |
| 89 | subthalamic nucleus |
| 89 | Motor control |
| 88 | depression |
| 88 | dementia |
| 88 | Ubiquitin-Protein Ligases (genetics) |
| 88 | Parkinsonian Disorders (complications) |
| 88 | Incidence |
| 88 | Basal Ganglia (physiopathology) |
| 87 | epidemiology |
| 87 | Deep Brain Stimulation |
| 87 | Antipsychotic Agents (adverse effects) |
| 86 | genetics |
| 86 | Tomography, Emission-Computed |
| 86 | Thalamus |
| 85 | Toxin |
| 85 | Review |
| 85 | Brain (radionuclide imaging) |
| 84 | Torticollis (drug therapy) |
| 84 | Dyskinesia, Drug-Induced (diagnosis) |
| 84 | Dopamine Agonists (adverse effects) |
| 84 | Anticonvulsants (therapeutic use) |
| 83 | Single photon emission tomography |
| 83 | Corpus Striatum (physiopathology) |
| 82 | Rats |
| 82 | Neurons (pathology) |
| 82 | Evaluation scale |
| 81 | basal ganglia |
| 81 | Tremor (drug therapy) |
| 81 | Neuromuscular Agents (therapeutic use) |
| 81 | Globus Pallidus (physiopathology) |
| 80 | dyskinesia |
| 80 | Sex Factors |
| 80 | Huntington Disease (diagnosis) |
| 80 | Alleles |
| 79 | Huntington Disease (physiopathology) |
| 79 | Huntington Disease (complications) |
| 78 | Neuroleptic |
| 78 | Hand |
| 78 | Gene Frequency |
| 78 | Dystonia (complications) |
| 78 | Corpus Striatum (radionuclide imaging) |
| 77 | quality of life |
| 77 | Radiopharmaceuticals (diagnostic use) |
| 77 | Pallidum |
| 77 | Motor system disorder |
| 77 | Dopamine Agents (therapeutic use) |
| 77 | Corpus Striatum (metabolism) |
| 77 | Botulinum Toxins (therapeutic use) |
| 77 | Animal model |
| 76 | Torticollis (physiopathology) |
| 76 | Positron-Emission Tomography |
| 76 | Parkinsonian Disorders (physiopathology) |
| 75 | Subthalamic Nucleus (physiopathology) |
| 75 | Posture (physiology) |
| 75 | Pathology |
| 75 | Globus Pallidus (surgery) |
| 75 | Essential Tremor (physiopathology) |
| 75 | Dyskinesia, Drug-Induced (drug therapy) |
| 75 | Chi-Square Distribution |
| 74 | Regression Analysis |
| 74 | Essential |
| 74 | Chorea (diagnosis) |
| 74 | Anti-Dyskinesia Agents (therapeutic use) |
| 73 | progressive supranuclear palsy |
| 73 | Spinocerebellar ataxia |
| 73 | Sleep disorder |
| 73 | Myoclonus (diagnosis) |
| 73 | Genetic Predisposition to Disease (genetics) |
| 73 | Evoked Potentials, Motor (physiology) |
| 73 | Essential Tremor (diagnosis) |
| 73 | Dystonia (therapy) |
| 73 | Depression (etiology) |
| 73 | Cross-Over Studies |
| 72 | alpha-Synuclein (genetics) |
| 72 | Supranuclear Palsy, Progressive (diagnosis) |
| 72 | Antipsychotic Agents (therapeutic use) |
| 72 | Antiparkinson Agents (pharmacology) |
| 71 | Tic |
| 71 | Extrapyramidal syndrome |
| 70 | Multiple System Atrophy (pathology) |
| 70 | Infant |
| 70 | Globus Pallidus (pathology) |
| 70 | Dopamine receptor |
| 70 | Chorea (etiology) |
| 70 | Brain (drug effects) |
| 69 | Supranuclear Palsy, Progressive (pathology) |
| 69 | Multiple System Atrophy (physiopathology) |
| 69 | Electric Stimulation Therapy |
| 69 | Dysfunction |
| 68 | alpha-Synuclein (metabolism) |
| 68 | Positron |
| 68 | Odds Ratio |
| 68 | Instrumental stimulation |
| 68 | Behavior |
| 67 | Postural Balance (physiology) |
| 67 | Nuclear Proteins (genetics) |
| 67 | Monkey |
| 67 | Globus Pallidus (physiology) |
| 67 | Drug Combinations |
| 67 | Carbidopa (therapeutic use) |
| 65 | United States |
| 65 | Tremor (genetics) |
| 65 | Torticollis (diagnosis) |
| 65 | Restless Legs Syndrome (diagnosis) |
| 65 | Polymerase Chain Reaction |
| 65 | Myoclonus (etiology) |
| 65 | Age of onset |
| 64 | Motor Activity (drug effects) |
| 64 | Medical screening |
| 64 | Dementia (diagnosis) |
| 64 | Chorea (physiopathology) |
| 63 | Mice |
| 63 | Genetic Testing |
| 63 | Exons (genetics) |
| 63 | Dystonia (pathology) |
| 62 | botulinum toxin |
| 62 | Tomography, Emission-Computed, Single-Photon (methods) |
| 62 | Muscle, Skeletal (innervation) |
| 62 | Movement Disorders (drug therapy) |
| 62 | Gait (physiology) |
| 62 | Comorbidity |
| 62 | Biomechanical Phenomena |
| 61 | Tropanes (diagnostic use) |
| 61 | Polymorphism |
| 61 | Movement Disorders (complications) |
| 61 | Levodopa (pharmacology) |
| 61 | Dyskinesias (etiology) |
| 61 | D2 Dopamine receptor |
| 60 | Walking |
| 60 | Unilateral |
| 60 | Substantia Nigra (physiopathology) |
| 60 | Putamen (pathology) |
| 60 | Parkinson Disease (blood) |
| 60 | Pain |
| 60 | Dementia (complications) |
| 60 | Carbidopa (administration & dosage) |
| 59 | myoclonus |
| 59 | Neural Pathways (physiopathology) |
| 59 | Motor Skills (physiology) |
| 59 | History, 19th Century |
| 59 | Gait |
| 59 | Dystonia (chemically induced) |
| 59 | Dopamine (physiology) |
| 58 | Polymorphism, Genetic (genetics) |
| 58 | Parkinson Disease (rehabilitation) |
| 58 | Locus niger |
| 58 | Freezing |
| 58 | Electromyography (drug effects) |
| 58 | Electric Stimulation |
| 58 | Deep Brain Stimulation (adverse effects) |
| 57 | Surgery |
| 57 | Spasmodic torticollis |
| 57 | Neurons (metabolism) |
| 57 | Nerve Degeneration (pathology) |
| 57 | Myoclonus (drug therapy) |
| 57 | Movement Disorders (therapy) |
| 57 | Motor Neurons (physiology) |
| 57 | Basal Ganglia Diseases (diagnosis) |
| 57 | Attention (physiology) |
| 57 | Atrophy (pathology) |
| 56 | dopamine |
| 56 | Risk |
| 56 | Psychogenic |
| 56 | Polymorphism, Single Nucleotide (genetics) |
| 56 | Parkinson Disease, Secondary (diagnosis) |
| 56 | Parkinson Disease (classification) |
| 56 | Dyskinesia, Drug-Induced (physiopathology) |
| 56 | Double blind study |
| 55 | Placebo |
| 55 | Neurons (physiology) |
| 55 | Motor Skills (drug effects) |
| 55 | Logistic Models |
| 55 | Late |
| 55 | Fatal Outcome |
| 55 | Corpus Striatum (drug effects) |
| 55 | Combined Modality Therapy |
| 55 | Chorea (genetics) |
| 54 | chorea |
| 54 | Neural Inhibition (physiology) |
| 54 | Corpus striatum |
| 54 | Botulinum Toxins (administration & dosage) |
| 53 | Trinucleotide Repeat Expansion (genetics) |
| 53 | Tremor (complications) |
| 53 | Questionnaire |
| 53 | Lewy Bodies (pathology) |
| 53 | Dystonic Disorders (therapy) |
| 53 | Clinical Trials as Topic |
| 53 | Cerebral cortex |
| 53 | Carbidopa (adverse effects) |
| 52 | Tremor (therapy) |
| 52 | Substantia Nigra (drug effects) |
| 52 | Progressive |
| 52 | Iodine Radioisotopes (diagnostic use) |
| 52 | Brain Stem (physiopathology) |
| 52 | Botulinum Toxins, Type A (administration & dosage) |
| 51 | gait |
| 51 | SPECT |
| 51 | Reaction Time |
| 51 | Rapid eye movement sleep |
| 51 | Neuroprotective Agents (therapeutic use) |
| 51 | Concomitant disease |
| 51 | Cognition (physiology) |
| 51 | Case control study |
| 50 | Walking (physiology) |
| 50 | Transcranial magnetic stimulation |
| 50 | Stereotaxic Techniques |
| 50 | Randomized Controlled Trials as Topic |
| 50 | Movement Disorders (genetics) |
| 50 | Frontal Lobe (physiopathology) |
| 50 | Evoked Potentials, Somatosensory (physiology) |
| 50 | Essential tremor |
| 50 | Electrical stimulus |
| 50 | Dopamine Agents (adverse effects) |
| 50 | Cognition Disorders (epidemiology) |
| 50 | Clostridium botulinum |
| 50 | Clinical form |
| 50 | Cerebellum (physiopathology) |
| 50 | Autopsy |
| 49 | Video Recording |
| 49 | Psychomotor Performance |
| 49 | Immunohistochemistry |
| 49 | Fluorodeoxyglucose F18 (diagnostic use) |
| 49 | Fluctuations |
| 48 | Supranuclear Palsy, Progressive (physiopathology) |
| 48 | Substantia Nigra (metabolism) |
| 48 | Spinocerebellar Ataxias (genetics) |
| 48 | Restless Legs Syndrome (physiopathology) |
| 48 | Psychosis |
| 48 | Parkinsonian Disorders (etiology) |
| 48 | Parkin |
| 48 | Multiple System Atrophy (complications) |
| 48 | Lewy body |
| 48 | Head |
| 48 | Genetic determinism |
| 48 | Dystonic Disorders (etiology) |
| 48 | Demography |
| 48 | Advanced stage |
| 47 | transcranial magnetic stimulation |
| 47 | Writer cramp |
| 47 | Parkinsonian Disorders (epidemiology) |
| 47 | Parkinson Disease, Secondary (physiopathology) |
| 47 | Movement |
| 47 | Molecular Chaperones (genetics) |
| 47 | Genetics |
| 47 | Basal Ganglia Diseases (physiopathology) |
| 46 | movement disorders |
| 46 | Tourette Syndrome (physiopathology) |
| 46 | Sporadic |
| 46 | ROC Curve |
| 46 | Parkinson Disease (mortality) |
| 46 | Myoclonus (genetics) |
| 46 | Myoclonus (complications) |
| 46 | MRI |
| 46 | Lewy body dementia |
| 46 | Heterozygote Detection |
| 46 | Handwriting |
| 45 | treatment |
| 45 | cognition |
| 45 | Subthalamic Nucleus (surgery) |
| 45 | Neck |
| 45 | Confidence Intervals |
| 45 | Bilateral |
| 45 | Activities of Daily Living (classification) |
| 44 | Parkinsonian Disorders (radionuclide imaging) |
| 44 | Parkinson Disease, Secondary (drug therapy) |
| 44 | PET |
| 44 | Neurologic Examination (statistics & numerical data) |
| 44 | Essential Tremor (epidemiology) |
| 44 | Cognition Disorders (psychology) |
| 44 | Cerebrospinal fluid |
| 44 | Anxiety |
| 43 | sleep |
| 43 | cervical dystonia |
| 43 | Transcranial Magnetic Stimulation |
| 43 | Torticollis |
| 43 | Recurrence |
| 43 | Rat |
